Shionogi & Co. Ltd filed a Schedule 13G with the SEC on November 4, 2026, reporting beneficial ownership of 2,953,817 shares of Apnimed, Inc. common stock as of September 30, 2026.

Key Highlights

  • Reporting person: Shionogi & Co. Ltd, a corporation organized in Japan.
  • Shares beneficially owned: 2,953,817 shares of Apnimed, Inc. Common Stock, par value $0.00001 per share.
  • Percent of class: 7.10%, calculated based on 41,630,779 shares outstanding as of September 4, 2026.
  • Voting and dispositive power: Sole voting power and sole dispositive power over all 2,953,817 shares; no shared voting or dispositive power reported.
  • Triggering date: The event requiring filing occurred on September 30, 2026.
  • Issuer address: 39 John F. Kennedy Street, 4th Floor, Cambridge, Massachusetts 02138, according to the filing.

Shionogi's Schedule 13G Filing on Apnimed Common Stock

According to the Schedule 13G filed November 4, 2026, Shionogi & Co. Ltd, headquartered at Grand Green Osaka South Building Park Tower 26F, 5-54 Ofukacho, Kita-ku, Osaka, Japan 530-0011, disclosed beneficial ownership of 2,953,817 shares of Apnimed, Inc. common stock. The filing identifies the CUSIP number for the securities as 03770Y107. The date of the event requiring the filing is listed as September 30, 2026.

The filing reports that Shionogi holds sole voting power and sole dispositive power over all 2,953,817 shares, with zero shared voting or dispositive power. The 7.10% ownership percentage, as stated in the filing, is "calculated based on 41,630,779 shares of Common Stock issued and outstanding as of September 4, 2026, as reported by the issuer in its quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2026, filed with the Securities and Exchange Commission on September 8, 2026."

The filing was signed by Isao Teshirogi, Ph.D., identified as Representative Director, President and CEO of Shionogi & Co. Ltd, and dated November 4, 2026. The filing does not identify Apnimed's exchange or ticker symbol in the Schedule 13G text. The type of reporting person is designated as "CO" (corporation). Items relating to group membership, subsidiary identification, and ownership on behalf of another person are each marked "Not Applicable" in the filing.

What Was Disclosed

Shionogi & Co. Ltd filed a Schedule 13G disclosing a 7.10% beneficial ownership stake, equating to 2,953,817 shares, in Apnimed, Inc. common stock, with the triggering event dated September 30, 2026, and the filing submitted November 4, 2026.